Frazier Life Sciences Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Frazier Life Sciences Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-983,715	Closed	-$29.6M	–	50
2025 Q3	$29.6M	Hold	983,715	–	–	0.89%	24
2025 Q2	$35.8M	Buy	983,715 +325,000	+49%	+$11.7M	1.43%	17
2025 Q1	$23.9M	Hold	658,715	–	–	1.09%	20
2024 Q4	$27.7M	Buy	658,715 +25,000	+4%	+$1.24M	1.15%	21
2024 Q3	$35.2M	Buy	633,715 +208,715	+49%	+$10.6M	1.41%	21
2024 Q2	$17.5M	Buy	+425,000	New	+$18.1M	0.82%	28

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Frazier Life Sciences Management's RARE Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 983,715 shares — an estimated $29.6M sold.

Frazier Life Sciences Management first reported a position in RARE in Q2 2024 and held it in 6 quarters. The position peaked at $35.8M in Q2 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Frazier Life Sciences Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 983,715 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $29.6M.
Frazier Life Sciences Management first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and held it in 6 quarters.
Frazier Life Sciences Management's Ultragenyx Pharmaceutical position peaked at $35.8M in Q2 2025.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.